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Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO, United StatesExercise is one of the best therapies, if not the best, for the preven-
tion and treatment of type 2 diabetes. Kondo, Araki, Kai and colleagues,
in this issue of EBioMedicine, introduce a device that mimics exercise
(1). When applied to subjects with metabolic syndrome (MS) or type
2 diabetes (t2DM) the therapy improves the diverse parameters inherit
to metabolic syndrome (MS) and type 2 diabetes (t2DM)—inﬂamma-
tion, hypertension, glycemia, dyslipidemia, abdominal obesity, body
weight, and insulin signaling. The results are a quantum leap toward un-
derstanding type 2 diabetes and treating it. The researchers are to be
congratulated in their single-minded quest to move from the bench to
the bedside. As they sought methods to duplicate the beneﬁcial effects
of exercise, their research moved from heat, to heat shock proteins
(Hsps, also known as stress proteins), to a tailored electrical-heat stim-
ulation that maximizes Hsp induction.
Speciﬁcally, Kondo and colleagues studied 40 patients with MS or
t2DM in a randomized crossover trial of 12 weeks of therapy with
mild electric stimulation and heat shock (MES + HS) versus no inter-
vention for 12 weeks. The device transmits direct electric current and
heat through the upper abdomen, ﬁtting like a cumberbund. MES + HS
was applied for 1 h four times per week. Improvements in glycemic,
lipid, and fat deposition measurements were more pronounced in t2DM
thanMS. Of particular note was a .72% reduction in A1c in t2DM subjects
with higher baseline levels (7.6–10.0%) (Kondo et al., 2014). This level of
reduction is similar to that seen by recently introduced drugs like
sitagliptin (a dipeptidyl peptidase 4 (DPP-4) inhibitor) that drops A1c
.6% when used in monotherapy (Zerilli and Pyon, 2007).
A remarkable 55% drop in albuminuria was observed in t2DMwith a
drop in serum creatinine. The fall in albuminuria is in the same order of
magnitude as observedwith ACE inhibitor therapy (Yilmaz et al., 2010).
The same research group has demonstrated MES + HS reduced renal
function loss in an animal model of renal failure (Koga et al., 2012).
Regarding its efﬁcacy in reducing inﬂammation in MS, MES + HS
dropped hs-CRP by 54%. hs-CRP in t2DM improves prediction of cardio-
vascular disease and has been suggested that itsmeasurement be added
to the deﬁnition of metabolic syndrome. The reduction in inﬂammation
cannot be understated, as cardiovascular disease is indeed the major
cause of mortality in these disease states (Haffner, 2006). The 54%
drop in hs-CRP compares favorablywith the drop observedwith atorva-
statin (35%) in t2DM patients (Sindhu et al., 2011).DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2014.11.001.
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muscle and liver may be the near sentinel event in the development
of MET or t2DM. Lowmuscle intracellular Hsp precedes abnormal met-
abolic function by four years in non-human primateswhich is compara-
ble to a decade in humans (Chichester et al., 2014). Furthermore,
normo-glycemic identical twins of siblings with impaired glucose toler-
ance have lowmuscle Hsp expression. Restoring the low Hsps via exer-
cise or bioactive Hsp inducers normalizes the pathologic features of MS
and t2DM. Hsp induction stimulates survival pathways like AMPK that
limits fat storage while activating fat catabolism. Mitochondria biogen-
esis and mitochondrial function are improved by Hsp induction—aug-
menting reduction in adipose stores. Inﬂammation is markedly
improved with major reductions in CRP and cytokine activation—
blocking the vicious cycle of inﬂammation, reduced insulin signaling
which further impairs Hsp expression and thus promotes more inﬂam-
mation (Hooper et al., 2014).
MS and t2DM put organs in peril—from neuropathies, to retinopa-
thies, to myopathies, to nephropathies, to hepatic seatosis, to dementia.
Restoring Hsps in diabetic animal models limits the diabetic complica-
tions. Reduction in systemic inﬂammation will likely reduce the vascu-
lar disease so prevalent in these diseases. Mild electric stimulation
(MES) indeed reduces nephropathy and fatty liver. Similarly, MES
+HS augments pancreatic beta-cell function in animal diabetic models
(Kondo et al., 2012).
The health care provider is often frustrated by limited efﬁcacious ther-
apies available to prevent and treat themetabolic disease epidemic.While
life-style modiﬁcation remains the initial and most effective therapy,
long-term compliance often does not endure. Can the MES + HS device
be used throughout the course of this syndrome-complex? Certainly, a di-
abetic individual with proteinuria and an elevated serum creatinine is a
candidate for a MES + HS device to use in their home. The same is true
for hepatic seatosis with progressive liver injury. Of course, how will the
device be used in clinics or at home?Howexpensivewill it be? Can a sim-
ilar device be used for other therapies—arthritis, wound healing, and
heart failure—where an augmented cellular stress responsemay be bene-
ﬁcial? MES + HS efﬁcacy is comparable if not better than present main-
stay pharmaceutical agents. Furthermore, MES + HS is broadly effective
in normalizing the whole spectrum of pathologic defects associated
with MS and t2DM—not unlike the effect of regular exercise.
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